Gene Therapy and Hemophilia: Where Do We Go from Here?

References

• Konkle BA, Huston H, Nakaya Fletcher S, et al. Hemophilia A. In: Adam MP, Ardinger HH, Pagon RA, editors. Genereviews(R). Seattle WA: University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle; 1993.
   Google Scholar
• Konkle BA, Huston H, Nakaya Fletcher S, et al. Hemophilia B. In: Adam MP, Ardinger HH, Pagon RA, editors. Genereviews(R). Seattle WA: University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle; 1993.
   Google Scholar
• Hay CRM, Nissen F, Pipe SW. Mortality in congenital hemophilia A - A systematic literature review. J Thrombosis Haemostasis. 2021;19(Suppl1):6–20. doi:10.1111/jth.15189
   PubMed Web of Science ®Google Scholar
• Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007;110(3):815–825. doi:10.1182/blood-2006-10-050435
   PubMed Web of Science ®Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158. doi:10.1111/hae.14046
   PubMed Web of Science ®Google Scholar
• World Federation of Hemophilia. The report on the WFH annual global survey 2020; 2021. Available from: https://www1.wfh.org/publications/files/pdf-2045.pdf. Accessed September 22, 2022.
   Google Scholar
• Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia. 2010;16(1):20–32. doi:10.1111/j.1365-2516.2009.02127.x
   PubMed Web of Science ®Google Scholar
• Stonebraker JS, Bolton-Maggs PH, Michael Soucie J, Walker I, Brooker M. A study of variations in the reported haemophilia B prevalence around the world. Haemophilia. 2012;18(3):e91–94. doi:10.1111/j.1365-2516.2011.02588.x
   PubMed Web of Science ®Google Scholar
• Nathwani AC. Gene therapy for hemophilia. Hematol Am Soc Hematol Educ Program. 2019;2019(1):1–8. doi:10.1182/hematology.2019000007
   PubMed Web of Science ®Google Scholar
• NIH U.S. National Library of Medicine; 2022. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/. Accessed April 25, 2022.
   Google Scholar
• Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003;101(8):2963–2972. doi:10.1182/blood-2002-10-3296
   PubMed Web of Science ®Google Scholar
• Jiang H, Pierce GF, Ozelo MC, et al. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther. 2006;14(3):452–455. doi:10.1016/j.ymthe.2006.05.004
   PubMed Web of Science ®Google Scholar
• Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342–347. doi:10.1038/nm1358
   PubMed Web of Science ®Google Scholar
• George LA, Ragni MV, Rasko JEJ, et al. Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B. Mol Ther. 2020;28(9):2073–2082. doi:10.1016/j.ymthe.2020.06.001
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357–2365. doi:10.1056/NEJMoa1108046
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371(21):1994–2004. doi:10.1056/NEJMoa1407309
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Reiss UM, Tuddenham EG, et al. Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing “empty viral particles” on safety and efficacy of gene transfer [abstract]. Blood. 2018;132:491. doi:10.1182/blood-2018-99-118334
   Web of Science ®Google Scholar
• Leebeek FWG, Miesbach W. Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues. Blood. 2021;138(11):923–931. doi:10.1182/blood.2019003777
   PubMed Web of Science ®Google Scholar
• Miesbach W, Meijer K, Coppens M, et al. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood. 2018;131(9):1022–1031. doi:10.1182/blood-2017-09-804419
   PubMed Web of Science ®Google Scholar
• Miesbach W, Meijer K, Coppens M, et al. Five year data confirms stable FIX expression and sustained reductions in bleeding and factor IX use following AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B [abstract]. Res Pract Thrombosis Haemostasis. 2021;5:90.
   Google Scholar
• Von Drygalski A, Giermasz A, Castaman G, et al. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv. 2019;3(21):3241–3247. doi:10.1182/bloodadvances.2019000811
   PubMed Web of Science ®Google Scholar
• Miesbach W, Leebeek FWG, Recht M, et al. Final analysis from the pivotal phase 3 Hope-B gene therapy trial: stable steady-state efficacy and safety of etranacogene dezaparvovec in adults with severe or moderately severe hemophilia B [abstract]. Haemophilia. 2022;28:99–100.
   Web of Science ®Google Scholar
• George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377(23):2215–2227. doi:10.1056/NEJMoa1708538
   PubMed Web of Science ®Google Scholar
• George LA, Sullivan SK, Rasko JEJ, et al. Efficacy and safety in 15 hemophilia B patients treated with the AAV gene therapy vector fidanacogene elaparvovec and followed for at least 1 year [abstract]. Blood. 2019;134:3347. doi:10.1182/blood-2019-124091
   Web of Science ®Google Scholar
• Chowdary P, Shapiro S, Makris M, et al. Phase 1–2 trial of AAVS3 gene therapy in patients with hemophilia B. N Engl J Med. 2022;387(3):237–247. doi:10.1056/NEJMoa2119913
   PubMed Web of Science ®Google Scholar
• Konkle BA, Walsh CE, Escobar MA, et al. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood. 2021;137(6):763–774. doi:10.1182/blood.2019004625
   PubMed Web of Science ®Google Scholar
• Calcedo R, Kuri-Cervantes L, Peng H, et al. Immune responses in 101HEMB01, a phase 1/2 open-label, single ascending dose-finding trial of DTX101 (AAVrh10FIX) in patients with severe hemophilia B [abstract]. Blood. 2017;130:3333.
   Web of Science ®Google Scholar
• Pipe SW, Gonen-Yaacovi G, Segurado OG. Hemophilia A gene therapy: current and next-generation approaches. Expert Opin Biol Ther. 2022;2022:1–17.
   Google Scholar
• Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med. 2022;386(11):1013–1025. doi:10.1056/NEJMoa2113708
   PubMed Web of Science ®Google Scholar
• Rangarajan S, Walsh L, Lester W, et al. AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J Med. 2017;377(26):2519–2530. doi:10.1056/NEJMoa1708483
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N Engl J Med. 2020;382(1):29–40. doi:10.1056/NEJMoa1908490
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Laffan M, Rangarajan S, et al. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. Haemophilia. 2021;27(6):947–956. doi:10.1111/hae.14391
   PubMed Web of Science ®Google Scholar
• Arruda VR. Why is AAV FVIII gene therapy not approved by the US Food and Drug Administration yet? Blood Adv. 2021;5(20):4313. doi:10.1182/bloodadvances.2021004760
   PubMed Web of Science ®Google Scholar
• Fong S, Yates B, Sihn CR, et al. Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A. Nat Med. 2022;28(4):789–797. doi:10.1038/s41591-022-01751-0
   PubMed Web of Science ®Google Scholar
• George LA, Monahan PE, Eyster ME, et al. Multiyear factor VIII expression after AAV gene transfer for hemophilia A. N Engl J Med. 2021;385(21):1961–1973. doi:10.1056/NEJMoa2104205
   PubMed Web of Science ®Google Scholar
• Sullivan SK, Barrett JC, Drelich DA, et al. SPK-8016: preliminary results from a phase 1/2 clinical trial of gene therapy for hemophilia A [abstract]. Haemophilia. 2021;27:129. doi:10.1111/hae.14190
   PubMed Web of Science ®Google Scholar
• Vishweshwar N, Harrington TJ, Leavitt AD, et al. Updated results of the Alta study, a phase 1/2 study of giroctocogene fitelparvovec (PF-07055480/SB-525) gene therapy in adults with severe hemophilia A [abstract]. Blood. 2021;138:564. doi:10.1182/blood-2021-148651
   Web of Science ®Google Scholar
• Pipe SW, Hay C, Sheehan J, et al. Evolution of AAV vector gene therapy is ongoing in hemophilia. Will the unique features of BAY 2599023 address the outstanding needs? [abstract]. Res Pract Thrombosis Haemostasis. 2021;5:1–7.
   Google Scholar
• Nathwani AC, Tuddenham EG, Chowdary P, et al. GO-8: preliminary results of a Phase I/II dose escalation trial of gene therapy for haemophlia A using a novel human factor VIII variant [abstract]. Blood. 2018;132:489. doi:10.1182/blood-2018-99-118256
   Web of Science ®Google Scholar
• Verdera HC, Kuranda K, Mingozzi F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther. 2020;28(3):723–746. doi:10.1016/j.ymthe.2019.12.010
   PubMed Web of Science ®Google Scholar
• Zou C, Vercauteren KOA, Michailidis E, et al. Experimental variables that affect human hepatocyte AAV transduction in liver chimeric mice. Mol Ther Methods Clin Dev. 2020;18:189–198. doi:10.1016/j.omtm.2020.05.033
   PubMed Web of Science ®Google Scholar
• Davidoff AM, Gray JT, Ng CY, et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther. 2005;11(6):875–888. doi:10.1016/j.ymthe.2004.12.022
   PubMed Web of Science ®Google Scholar
• Halbert CL, Rutledge EA, Allen JM, Russell DW, Miller AD. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol. 2000;74(3):1524–1532. doi:10.1128/JVI.74.3.1524-1532.2000
   PubMed Web of Science ®Google Scholar
• Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009;199(3):381–390. doi:10.1086/595830
   PubMed Web of Science ®Google Scholar
• Li C, Narkbunnam N, Samulski RJ, et al. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther. 2012;19(3):288–294. doi:10.1038/gt.2011.90
   PubMed Web of Science ®Google Scholar
• Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21(6):704–712. doi:10.1089/hum.2009.182
   PubMed Web of Science ®Google Scholar
• Kruzik A, Fetahagic D, Hartlieb B, et al. Prevalence of anti-adeno-associated virus immune responses in international cohorts of healthy donors. Mol Ther Methods Clin Dev. 2019;14:126–133. doi:10.1016/j.omtm.2019.05.014
   PubMed Web of Science ®Google Scholar
• Erles K, Sebökovà P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol. 1999;59(3):406–411. doi:10.1002/(SICI)1096-9071(199911)59:3<406:AID-JMV22>3.0.CO;2-N
   PubMed Web of Science ®Google Scholar
• Biomarin. Gene therapy study in severe hemophilia A patients with antibodies against AAV5 (270-203). MNLM identifier: NCT03520712. 2021.
   Google Scholar
• Scallan CD, Jiang H, Liu T, et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood. 2006;107(5):1810–1817. doi:10.1182/blood-2005-08-3229
   PubMed Web of Science ®Google Scholar
• Monahan PE, Négrier C, Tarantino M, Valentino LA, Mingozzi F. Emerging immunogenicity and genotoxicity considerations of adeno-associated virus vector gene therapy for hemophilia. J Clin Med. 2021;10(11):2471. doi:10.3390/jcm10112471
   PubMed Web of Science ®Google Scholar
• Sabatino DE, Bushman FD, Chandler RJ, et al. Evaluating the state of the science for adeno-associated virus integration: an integrated perspective. Mol Ther. 2022;30(8):2646–2663. doi:10.1016/j.ymthe.2022.06.004
   PubMed Web of Science ®Google Scholar
• D’Avola D, López-Franco E, Sangro B, et al. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. J Hepatol. 2016;65(4):776–783. doi:10.1016/j.jhep.2016.05.012
   PubMed Web of Science ®Google Scholar
• Kaeppel C, Beattie SG, Fronza R, et al. A largely random AAV integration profile after LPLD gene therapy. Nat Med. 2013;19(7):889–891. doi:10.1038/nm.3230
   PubMed Web of Science ®Google Scholar
• Uniqure.com. UniQure announces findings from reported case of hepatocellular carcinoma (HCC) in hemophilia B gene therapy program; 2021. Available from: https://wwwuniqurecom/PR_HCC%20Investigation%20Findings%20_3_29_21_FINALpdf. Accessed September 22, 2022.
   Google Scholar
• Konkle B, Pierce G, Coffin D, et al. Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: communication from the SSC of the ISTH. J Thrombosis Haemostasis. 2020;18(11):3074–3077. doi:10.1111/jth.15023
   PubMed Web of Science ®Google Scholar
• Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50. doi:10.1186/1748-5908-4-50
   PubMed Web of Science ®Google Scholar
• Pfadenhauer LM, Gerhardus A, Mozygemba K, et al. Making sense of complexity in context and implementation: the Context and Implementation of Complex Interventions (CICI) framework. Implement Sci. 2017;12(1):21. doi:10.1186/s13012-017-0552-5
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Human gene therapy for hemophilia. Guidance for industry; 2020. Available from: https://wwwfdagov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances. Accessed September 22, 2022.
   Google Scholar
• Agency EM. EMA’s scientific guidelines on gene therapy; 2022. Available from: https://wwwemaeuropaeu/en/human-regulatory/research-development/scientific-guidelines/multidisciplinary/multidisciplinary-gene-therapy. Accessed September 22, 2022.
   Google Scholar
• World Health Organization. WHO considerations on regulatory convergence of cell and gene therapy products; 2021:1–22. Available from: https://cdnwhoint/media/docs/default-source/biologicals/ecbs/who-public-consultation_cgtp-white-paper_16_dec_2021pdf?sfvrsn=18f6c549_5. Accessed September 22, 2022.
   Google Scholar
• Drago D, Foss-Campbell B, Wonnacott K, Barrett D, Ndu A. Global regulatory progress in delivering on the promise of gene therapies for unmet medical needs. Mol Ther Methods Clin Dev. 2021;21:524–529. doi:10.1016/j.omtm.2021.04.001
   PubMed Web of Science ®Google Scholar
• Reiss UM, Mahlangu J, Ohmori T, Ozelo MC, Srivastava A, Zhang L. Haemophilia gene therapy - update on new country initiatives. Haemophilia. 2022;28:61–67. doi:10.1111/hae.14512
   PubMed Web of Science ®Google Scholar
• Reiss UM, Zhang L, Ohmori T. Hemophilia gene therapy-new country initiatives. Haemophilia. 2021;27(Suppl 3):132–141. doi:10.1111/hae.14080
   PubMed Web of Science ®Google Scholar
• World Federation of Hemophilia. Gene therapy for hemophilia; 2019. Available from: https://elearning.wfh.org/resource/gene-therapy-for-hemophilia/. Accessed September 22, 2022.
   Google Scholar
• National Hemophilia Foundation. Gene and innovative therapies education. Available from: https://www.hemophilia.org/educational-programs/education/gene-and-innovative-therapies-education. Accessed March 10, 2022.
   Google Scholar
• American Society of Gene and Cell Therapy. Hemophilia. Available from: https://patienteducation.asgct.org/disease-treatments/hemophilia. Accessed October 22, 2020.
   Google Scholar
• International Society on Thrombosis and Hemostatis. Gene therapy in hemophilia an ISTH education initiative. Available from: https://genetherapy.isth.org/. Accessed September 29, 2021.
   Google Scholar
• Dionyssopoulos A, Karalis T, Panitsides EA. Continuing medical education revisited: theoretical assumptions and practical implications: a qualitative study. BMC Med Educ. 2014;14:1051. doi:10.1186/s12909-014-0278-x
   PubMedGoogle Scholar
• Vasquez-Loarte TC, Lucas TL, Harris-Wai J, Bowen DJ. Beliefs and values about gene therapy and in-utero gene editing in patients with hemophilia and their relatives. Patient. 2020;13(5):633–642. doi:10.1007/s40271-020-00442-7
   PubMedGoogle Scholar
• Witkop M, Morgan G, O’Hara J, et al. Patient preferences and priorities for haemophilia gene therapy in the US: a discrete choice experiment. Haemophilia. 2021;27(5):769–782. doi:10.1111/hae.14383
   PubMed Web of Science ®Google Scholar
• van Overbeeke E, Michelsen S, Hauber B, et al. Patient perspectives regarding gene therapy in haemophilia: interviews from the PAVING study. Haemophilia. 2020;27:129–136.
   PubMed Web of Science ®Google Scholar
• Tingley K, Coyle D, Graham ID, et al. Stakeholder perspectives on clinical research related to therapies for rare diseases: therapeutic misconception and the value of research. Orphanet J Rare Dis. 2021;16(1):26. doi:10.1186/s13023-020-01624-0
   PubMed Web of Science ®Google Scholar
• Anderson EE, Newman SB, Matthews AK. Improving informed consent: stakeholder views. AJOB Empir Bioeth. 2017;8(3):178–188. doi:10.1080/23294515.2017.1362488
   PubMedGoogle Scholar
• Krumb E, Lambert C, Hermans C. Patient selection for hemophilia gene therapy: real-life data from a single center. Res Pract Thrombosis Haemostasis. 2021;5(3):390–394. doi:10.1002/rth2.12494
   PubMed Web of Science ®Google Scholar
• Sidonio RF, Pipe SW, Callaghan MU, Valentino LA, Monahan PE, Croteau SE. Discussing investigational AAV gene therapy with hemophilia patients: a guide. Blood Rev. 2021;47:100759. doi:10.1016/j.blre.2020.100759
   PubMed Web of Science ®Google Scholar
• Hart DP, Branchford BR, Hendry S, et al. Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study. Orphanet J Rare Dis. 2021;16(1):189. doi:10.1186/s13023-020-01555-w
   PubMed Web of Science ®Google Scholar
• Miesbach W, O’Mahony B, Key NS, Makris M. How to discuss gene therapy for haemophilia? A patient and physician perspective. Haemophilia. 2019;25(4):545–557. doi:10.1111/hae.13769
   PubMed Web of Science ®Google Scholar
• van Overbeeke E, Michelsen S, Toumi M, et al. Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. Drug Discov Today. 2020;26:399–415. doi:10.1016/j.drudis.2020.11.024
   PubMed Web of Science ®Google Scholar
• Garrison LP, Jiao B, Dabbous O. Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies. J Manag Care Special Pharm. 2021;27(5):674–681. doi:10.18553/jmcp.2021.27.5.674
   PubMed Web of Science ®Google Scholar
• Machin N, Ragni MV, Smith KJ. Gene therapy in hemophilia A: a cost-effectiveness analysis. Blood Adv. 2018;2(14):1792–1798. doi:10.1182/bloodadvances.2018021345
   PubMed Web of Science ®Google Scholar
• Cook K, Forbes SP, Adamski K, Ma JJ, Chawla A, Garrison LP. Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A. J Med Econ. 2020;23:1–12. doi:10.1080/13696998.2019.1678170
   PubMed Web of Science ®Google Scholar
• Rind D, Walton S, Agboola F. Valoctocogene Roxaparvovec and Emicizumab for Hemophilia A: Effectiveness and Value; Evidence Report. Institute for Clinical and Economic Review; 2020.
   Google Scholar
• Bolous NS, Chen Y, Wang H, et al. The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective. Blood. 2021;138:1677–1690. doi:10.1182/blood.2021010864
   PubMed Web of Science ®Google Scholar
• Ten Ham RM, Walker SM, Soares MO, et al. Modeling benefits, costs, and affordability of a novel gene therapy in hemophilia A. HemaSphere. 2022;6(2):e679. doi:10.1097/HS9.0000000000000679
   PubMed Web of Science ®Google Scholar
• Marsden G, Towse A, Pearson S, Dreitlein B, Henshall C. Gene therapy: understanding the science, assessing the evidence, and paying for value. 2017.
   Google Scholar
• Drummond MF, Neumann PJ, Sullivan SD, et al. Analytic considerations in applying a general economic evaluation reference case to gene therapy. Value Health. 2019;22(6):661–668. doi:10.1016/j.jval.2019.03.012
   PubMed Web of Science ®Google Scholar
• Garrison LP, Pezalla E, Towse A, et al. Hemophilia gene therapy value assessment: methodological challenges and recommendations. Value Health. 2021;24(11):1628–1633. doi:10.1016/j.jval.2021.05.008
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. Value assessment methods for “single or short-term transformative therapies” (SSTs); 2019. Available from: https://icerorg/wp-content/uploads/2020/10/ICER_SST_ProposedAdaptations_080619-2pdf. Accessed September 22, 2022.
   Google Scholar
• Maldonado R, Jalil S, Wartiovaara K. Curative gene therapies for rare diseases. J Community Genet. 2020;11:1–10. doi:10.1007/s12687-019-00448-1
   PubMed Web of Science ®Google Scholar
• Ma C-C, Wang Z-L, Xu T, He Z-Y, Wei Y-Q. The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnol Adv. 2020;40:107502. doi:10.1016/j.biotechadv.2019.107502
   PubMed Web of Science ®Google Scholar
• FDA. Statement from FDA Commissioner Scott Gottlieb, M.D. and Peter Marks, M.D., Ph.d., Director of the Center for Biologics Evaluation and Research on New Policies to Advance Development of Safe and Effective Cell and Gene Therapies. FDA; 2019.
   Google Scholar
• Goodman C, Berntorp E, Wong O; Council IHAS. Alternative payment models for durable and potentially curative therapies: the case of gene therapy for haemophilia A. Haemophilia. 2022;28:27–34. doi:10.1111/hae.14425
   PubMed Web of Science ®Google Scholar
• Noone D, Coffin D, Pierce GF. Reimbursing the value of gene therapy care in an era of uncertainty. Haemophilia. 2020;27:12–18.
   PubMed Web of Science ®Google Scholar
• Miesbach W, Chowdary P, Coppens M, et al. Delivery of AAV-based gene therapy through haemophilia centres-a need for re-evaluation of infrastructure and comprehensive care: a joint publication of EAHAD and EHC. Haemophilia. 2021;27(6):967–973. doi:10.1111/hae.14420
   PubMed Web of Science ®Google Scholar